Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions’ TxD ADC Collaboration Secures REACH Award from the New York Center for Biotechnology at the Stony Brook University

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license […]

Published April 8, 2025

Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 Inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation

Published March 23, 2022

Grant Award from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences

Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, NY, […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University